Xeris Biopharma Holdings CEO Paul Edick says the company is on track to reach cash flow breakeven by the end of 2023 if everything goes according to plan.
Speaking to Proactive, Edick said he is 'very confident' Xeris can achieve its fiscal 2022 and 2023 targets and is likely to generate $105 million to $120 million in net product revenue this year alone as its three products targeting endocrinology and neurology continue to gain traction.
Like other biotech companies, Edick said Xeris’ stock price has been under pressure. However, he said second-quarter earnings will provide more clarity on the success of its recently-launched Recorlev drug.
